Overview

• Seeking Alpha argues the stock has rebounded and is consolidating, suggesting the bottom is likely in with a 2026-focused outlook.
• Jim Cramer said he believes the shares have bottomed and recommended using call options rather than buying common stock.
• Analysis highlights persistent margin pressure from elevated medical costs and the integration of Amedisys.
• Regulatory risk remains a key overhang due to ongoing investigations and uncertainty around premium increases.
• Stronger Medicare Star Ratings could position the company for 2027 bonus revenues, with some institutional investors reportedly adding to positions.